Upstream / Downstream


Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, November 30th.

Thank you for your patience.

To Purchase # 5495SC

5495SC 100 µg (With Carrier) $199.00
5495SF 100 µg (Carrier Free) $199.00


Find answers on our FAQs page.


Visit PhosphoSitePlus®

PTM information and tools available.


Source / Purification

Recombinant human TGF-α (hTGF-α) Val40-Ala89 (Accession #NP_003227) was produced in E. coli at Cell Signaling Technology.

Product Description


>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hTGF-α. All lots are greater than 98% pure.

Molecular Formula:

Based on amino acid sequencing, greater than 50% of recombinant hTGF-α has a Met on the amino-terminal Val40 (MVVSH) and has a calculated MW of 5,683. The remainder starts at Val40 (VVSHF). DTT-reduced and non-reduced protein migrate as 5 kDa polypeptides.


The bioactivity of recombinant hTGF-α was determined in a MCF-10A cell proliferation assay. The ED50 of each lot is between 0.25-1.0 ng/ml.


Less than 0.01 ng endotoxin/1 μg hTGF-α.

Product Usage Information


With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hTGF-α. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

TGF-α is a member of the EGF family of proteins and is expressed by epithelial cells, keratinocytes, macrophages, and many tumor-derived cell lines (1-4). Soluble TGF-α is produced by proteolytic cleavage of a transmembrane precursor (5). TGF-α promotes cell proliferation and differentiation of a diverse array of cell types including cancer and neural cells (1,4,6). TGF-α binds to EGFR/ErbB1 and induces receptor dimerization and tyrosine kinase activation (7). TGF-α activates the MAPK pathways and involves Stat3 and Stat5 (1,6). Increased levels of TGF-α expression are associated with many cancers including breast cancer (1,8,9).

1.  Humphreys, R.C. and Hennighausen, L. (2000) Oncogene 19, 1085-91.

2.  Citri, A. and Yarden, Y. (2006) Nat Rev Mol Cell Biol 7, 505-16.

3.  Rappolee, D.A. et al. (1988) Science 241, 708-12.

4.  Higashiyama, S. et al. (2008) Cancer Sci 99, 214-20.

5.  Xu, X. et al. (1999) Oncogene 18, 5554-62.

6.  Ciana, P. et al. (2003) J Biol Chem 278, 31737-44.

7.  Song, J.I. and Grandis, J.R. (2000) Oncogene 19, 2489-95.

8.  Révillion, F. et al. (2008) Ann Oncol 19, 73-80.

9.  Masago, K. et al. (2008) Cancer Sci 99, 2295-301.

Entrez-Gene Id 7039
Swiss-Prot Acc. P01135

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Human Transforming Growth Factor α (hTGF-α)